Evaluation of thimerosal removal on immunogenicity of aluminum salts adjuvanted recombinant hepatitis B vaccine

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 1, 2012, Pages 39-46

  Mahboubi, Arash ^a   Fazeli, Mohammad Reza ^b   Samadi, Nasrin ^b   Dinarvand, Rasoul ^b   Azadi, Saeed ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Mfg Co Biotech Research Department   (Iran)

Author keywords

Aluminum salts; GMT; Hepatitis B vaccine; Relative potency; Thimerosal

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; RECOMBINANT HEPATITIS B VACCINE; THIOMERSAL;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; SEROCONVERSION;

EID: 84858595924     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Baker JP. Mercury, vaccines, and autism one controversy, three histories. Am. J. Public Health (2008) 98: 244-253.
2. Thimerosal in Vaccines, Questions and Answers. Vaccines, Blood and Biologics. Food and Drug Administration (FDA) [serial online] 2010 Mar Screen]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228.
3. Mehrgan H, Elmi F, Fazeli MR, Shahverdi AR and Samadi N. Evaluation of neutralizing efficacy and possible microbial cell toxicity of a universal neutralizer proposed by the CTPA. Iranian J. Pharm. Res. (2006) 3: 173-178.
4. Geier MR and Geier DA. Neurodevelopmental disordersafter thimerosal-containing vaccines: a brief communication. Exp. Biol. Med. (Maywood). (2003) 228: 660-664.
5. Ball LK, Ball R and Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics (2001) 107: 1147-54.
6. Rebedea I, Diaconescu IG, Bachc D, Bartelsen O and Arndtz N. Comparison of thimerosal-free and thimerosal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene®) in healthy adults. Vaccine (2006) 24: 5320-5326.
7. Mahboubi A, Fazeli MR, Dinarvand R, Samadi N, Sharifzadeh M, Ilka H, Azadi S, Soleimanian R, Kalkouei H, Hajikhanmirzaei R and Valadkhani M. Aluminum phosphate shows more adjuvanticity than aluminum hydroxide in recombinant hepatitis B vaccine formulation. Iranian J. Immunol. (2008) 5: 163-170.
8. Monograph. Hepatitis B Vaccine (Rdna). British Pharmacopeia (2010) 3:1056
9. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 227: 680-685.
10. Geier DA and Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr. Rehabil. (2003) 6: 97-102.
11. Geier DA and Geier MR. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis. Int. J. Toxicol. (2004) 23: 369-76.
12. Fombonne E, Zakarian R, Bennett A, Meng L and McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links withimmunizations. Pediatrics (2006) 118: e139-e150.
13. James SJ, Slikker W, Melnyk, New E, Pogribna M and Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology (2005) 26: 1-8.
14. Schultz ST. Does thimerosal or other mercury exposure increase the risk for autism? A review of current literature. Acta Neurobiol. Exp. (2010) 70: 187-195.